The dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice

Abstract Aim Tirzepatide (Tzp), a novel dual agonist glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1, is approved for treating insulin resistance and obesity, and menopausal women consuming a high‐calorie diet are a target to study the Tzp effect. Therefore, we aimed to allometrically scale body weight (BW) in Tzp‐treated obese diabetic menopausal mice. Materials and Methods Three‐month‐old C57BL/6 female mice had bilateral ovariectomy (Ovx) or a sham procedure and for 12 weeks were fed a control diet or a high‐fat and high sucrose diet ( n = 120/each group [control (C), obese diabetic (Od), Ovx (O), sham (S), Tzp (T)]). Tzp was subcutaneously administered (10 nmol/kg) or vehicle once a day for an additional 4 weeks. The analysis considered log‐transformed data and the allometric equation log y = log a + b log x . Results Od and OdO showed more upward slopes than C and CO. In C, BW was non‐allometric by T administration. Od and OdO showed slightly positive slopes (more prominent in OdO than Od). OdT and OdOT showed negative slopes, significant intercepts, and more robust Pearson coefficients than untreated ones. A potent drug effect was seen with BW allometric decline. Interactions between diet versus Ovx and diet versus Tzp affected weight gain. Diet versus Ovx versus Tzp affected food intake. Conclusions A model was developed to show three usual factors observed in mature women. Notably, Tzp improved the metabolism and weight loss of OdO mice. Tzp‐treated mice showed negative allometric BW across treatment time, which is a quantitative assessment that allows better comparison between results.